Disease Detail

ID DOID:50746
Name mantle cell lymphoma
Definition A B-cell lymphocytic neoplasm due to CD5 positive antigen-naive pregerminal center B-cell within the mantle zone that surrounds normal germinal center follicles.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer hematologic cancer lymphoma non-Hodgkin lymphoma B-cell lymphoma mantle cell lymphoma

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Unknown unknown ONC201 mantle cell lymphoma not applicable detail...
TP53 mutant RB1 wild-type R547 mantle cell lymphoma sensitive detail...
TP53 wild-type RB1 wild-type R547 mantle cell lymphoma sensitive detail...
Unknown unknown Abexinostat mantle cell lymphoma not applicable detail...
Unknown unknown Copanlisib mantle cell lymphoma not applicable detail...
Unknown unknown ST7612AA1 mantle cell lymphoma not applicable detail...
ATM inact mut Olaparib mantle cell lymphoma sensitive detail...
ATM inact mut Bendamustine + Olaparib mantle cell lymphoma sensitive detail...
ATM inact mut Olaparib + Valproic acid mantle cell lymphoma sensitive detail...
ATM inact mut Fludarabine + Olaparib mantle cell lymphoma sensitive detail...
Unknown unknown ONO-4059 mantle cell lymphoma not applicable detail...
Unknown unknown ONC201 + Venetoclax mantle cell lymphoma not applicable detail...
Unknown unknown Ibrutinib + ONC201 mantle cell lymphoma not applicable detail...
Unknown unknown BGB-3111 mantle cell lymphoma not applicable detail...
Unknown unknown GS-5829 + Venetoclax mantle cell lymphoma not applicable detail...
Unknown unknown Duvelisib mantle cell lymphoma not applicable detail...
Unknown unknown Bendamustine + Rituximab mantle cell lymphoma not applicable detail...
Unknown unknown Umbralisib mantle cell lymphoma not applicable detail...
Unknown unknown Ibrutinib mantle cell lymphoma not applicable detail...
Unknown unknown CC214-1 mantle cell lymphoma not applicable detail...
Unknown unknown Buparlisib + Ibrutinib mantle cell lymphoma not applicable detail...
Unknown unknown Ibrutinib + Palbociclib mantle cell lymphoma not applicable detail...
Unknown unknown Venetoclax mantle cell lymphoma not applicable detail...
Unknown unknown STRO-001 mantle cell lymphoma sensitive detail...
TP53 loss Bendamustine + Rituximab mantle cell lymphoma predicted - resistant detail...
TP53 loss Ibrutinib + Rituximab mantle cell lymphoma predicted - sensitive detail...
TP53 G244S Ibrutinib + Rituximab mantle cell lymphoma predicted - sensitive detail...
Unknown unknown Parsaclisib mantle cell lymphoma not applicable detail...
ATM mutant Ibrutinib + Venetoclax mantle cell lymphoma predicted - sensitive detail...
NOTCH1 mutant Ibrutinib + Venetoclax mantle cell lymphoma predicted - resistant detail...
Unknown unknown Lenalidomide mantle cell lymphoma not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00114738 Phase II Cyclophosphamide + Doxorubicin + Etoposide + Methylprednisolone + Rituximab + Vincristine Rituximab Bortezomib EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma Active, not recruiting
NCT00602693 Phase I Sirolimus Allopurinol + Cyclophosphamide + Fludarabine T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer Completed
NCT00671112 Phase I Bortezomib + Everolimus Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma Terminated
NCT00878254 Phase II Cyclophosphamide + Cytarabine + Doxorubicin + Etoposide + Filgrastim + Ifosfamide + Leucovorin + Mesna + Methotrexate + Rituximab + Vincristine Rituximab Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma Recruiting
NCT01111188 Phase I Bortezomib + Palbociclib Trial of PD 0332991 Plus Bortezomib in Patients With Relapsed Mantle Cell Lymphoma Active, not recruiting
NCT01180049 FDA approved Temsirolimus Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma Completed
NCT01251575 Phase II Fludarabine Cyclosporine + Mycophenolate mofetil + Sirolimus Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant Recruiting
NCT01267812 Phase II Bortezomib + Rituximab Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation Active, not recruiting
NCT01415752 Phase II Bortezomib Bendamustine Rituximab Lenalidomide Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma Recruiting
NCT01439750 Phase Ib/II Bortezomib + Cladribine + Rituximab Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011) Active, not recruiting
NCT01686165 Phase II Belinostat Rituximab Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma Completed
NCT01695941 Phase I Alisertib + Bortezomib + Rituximab Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma Active, not recruiting
NCT01719250 Phase I Buparlisib Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Completed
NCT01796171 Phase Ib/II Lilotomab Betalutin Rituximab A Phase I/II Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-01) Recruiting
NCT01799889 Phase II Entospletinib A Phase 2 of Entospletinib in Subjects With Relapsed or Refractory Hematologic Malignancies Active, not recruiting
NCT01804686 Phase III Ibrutinib A Long-term Extension Study of PCI-32765 (Ibrutinib) Enrolling by invitation
NCT01880567 Phase II Ibrutinib + Rituximab Phase 2 Ibrutinib + Rituximab in Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Recruiting
NCT01897012 Phase I Romidepsin Alisertib Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas Completed
NCT01905813 Phase I INCB040093 + Itacitinib INCB040093 Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies Active, not recruiting
NCT01955499 Phase I Ibrutinib + Lenalidomide Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Active, not recruiting
NCT01994382 Phase I Cerdulatinib Phase 1 Dose Escalation Study in Chronic Lymphocytic Leukemia and Non-hodgkin Lymphoma Recruiting
NCT02000934 Phase I TAK-659 A Study of TAK-659 in Adult Patients With Advanced Solid Tumor and Lymphoma Malignancies Active, not recruiting
NCT02018861 Phase I Itacitinib Itacitinib + Parsaclisib Bendamustine Rituximab Carboplatin + Etoposide + Ifosfamide Parsaclisib A Phase 1, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 Monotherapy and in Combination With INCB039110 in Subjects With Previously Treated B-Cell Malignancies Active, not recruiting
NCT02049541 Phase I Buparlisib + Rituximab Study of BKM120; Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma Active, not recruiting
NCT02106091 Phase I AFM11 Safety Study to Assess AFM11 in Patients With Relapsed and/or Refractory CD19 Positive B-cell NHL Terminated
NCT02159755 Phase I Ibrutinib + Palbociclib Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma Active, not recruiting
NCT02208037 Phase II Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) Completed
NCT02213926 Phase II Acalabrutinib An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma Active, not recruiting
NCT02242097 Phase II Ibrutinib Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma Active, not recruiting
NCT02268851 Phase I Ibrutinib + Umbralisib A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL Active, not recruiting
NCT02269085 Phase Ib/II Carfilzomib + Ibrutinib A Phase I/II Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma Terminated
NCT02285244 Phase II AEB071 Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's Transformation Withdrawn
NCT02303392 Phase I Ibrutinib + Selinexor Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma Recruiting
NCT02328014 Phase Ib/II ACP-319 Acalabrutinib ACP-196 in Combination With ACP-319, for Treatment of B-Cell Malignancies Active, not recruiting
NCT02339922 Phase II Ixazomib + Rituximab Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma Recruiting
NCT02381080 Phase I Erythromycin + Ibrutinib + Voriconazole Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy Completed
NCT02419560 Phase I Ibrutinib + Venetoclax Optimal Dose Finding Study ABT-199 and Ibrutinib in MCL Recruiting
NCT02420795 Phase Ib/II ONC201 Study of Oral ONC201 in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma Recruiting
NCT02427620 Phase II Cyclophosphamide + Doxorubicin + Vincristine Filgrastim Dexamethasone Cytarabine + Methotrexate Leucovorin A Study of Ibrutinib Plus Rituximab With Hyper-CVAD Consolidation in Newly Diagnosed Young Patients With Mantle Cell Lymphoma Active, not recruiting
NCT02440685 Phase Ib/II ASN002 A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors Terminated
NCT02446236 Phase I Ibrutinib + Lenalidomide + Rituximab Dose Finding Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma (MCL) Recruiting
NCT02454270 Phase II JNJ-64052781 A Dose Escalation Study of JNJ-64052781 in Participants With Relapsed or Refractory B-cell Malignancies Terminated
NCT02455297 Phase II Copanlisib Phase IIa Study of Copanlisib in Relapsed or Refractory Mantle Cell Lymphoma (MCL) Terminated
NCT02489123 Phase I Enzalutamide Enzalutamide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma Active, not recruiting
NCT02564744 Phase II IMGN529 + Rituximab Study to Evaluate the Efficacy and Tolerability Debio 1562 in Combination With Rituximab in Patients With Relapsed and/or Refractory DLBCL and Other Forms of NHL Recruiting
NCT02572453 Phase II Onalespib AT13387 in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Diffuse Large B-cell Lymphoma Recruiting
NCT02601313 Phase II Cyclophosphamide + Fludarabine + KTE-C19 A Phase 2 Multicenter Study Evaluating Subjects With Relapsed/Refractory Mantle Cell Lymphoma (ZUMA-2) Recruiting
NCT02603445 Phase I BCL201 + Idelalisib Study of Safety and Efficacy of BCL201 and Idelalisib in Patients With FL and MCL Completed
NCT02631044 Phase I JCAR017 Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) Recruiting
NCT02632396 Phase Ib/II Ixazomib + Rituximab Ixazomib & Rituximab After Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma in Remission Recruiting
NCT02650999 Phase Ib/II Pembrolizumab Study of Pembrolizumab in Patients Failing to Respond to or Relapsing After Anti-CD19 Chimeric Antigen Receptor Modified T Cell Therapy for Relapsed or Refractory CD19+ Lymphomas Active, not recruiting
NCT02717624 Phase I Acalabrutinib + Bendamustine + Rituximab A Study of ACP-196 in Combination With Bendamustine and Rituximab in Subjects With Mantle Cell Lymphoma Recruiting
NCT02722668 Phase II Cyclophosphamide + Fludarabine + Mycophenolate mofetil Sirolimus anti-thymocyte globulin UCB Transplant for Hematological DIseases Using a Non Myeloablative Prep Recruiting
NCT02736617 Phase II Ibrutinib + Obinutuzumab Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma Recruiting
NCT02743546 Phase I Ibrutinib + JNJ-64052781 Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of JNJ-64052781 Plus Ibrutinib in Lymphoma Withdrawn
NCT02745769 Phase I Merestinib + Ramucirumab Abemaciclib + Ramucirumab A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents Completed
NCT02756247 Phase I Buparlisib + Ibrutinib A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma Active, not recruiting
NCT02776813 Phase I ACTR087 + Rituximab Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma Active, not recruiting
NCT02869633 Phase II Ibrutinib Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant Recruiting
NCT02875002 Phase I Belinostat + Volasertib Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas Withdrawn
NCT02900716 Phase I DTRMWXHS-12 + Everolimus + Pomalidomide DTRMWXHS-12 DTRMWXHS-12 + Everolimus Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas Recruiting
NCT02931110 Phase I CBL0137 Study of IV CBL0137 in Previously Treated Hematological Subjects Recruiting
NCT02950220 Phase I Ibrutinib + Pembrolizumab Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Active, not recruiting
NCT02972840 Phase III Bendamustine + Rituximab Acalabrutinib + Bendamustine + Rituximab A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma Recruiting
NCT03010358 Phase Ib/II Entospletinib + Obinutuzumab Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma Recruiting
NCT03015896 Phase Ib/II Lenalidomide + Nivolumab Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma Recruiting
NCT03019640 Phase II Carmustine + Cytarabine + Etoposide + Filgrastim + Lenalidomide + Melphalan + Rituximab Immunotherapy With Ex Vivo-Expanded Cord Blood-Derived NK Cells Combined With Rituximab High-Dose Chemotherapy and Autologous Stem Cell Transplant for B-Cell Non-Hodgkin's Lymphoma Recruiting
NCT03028103 Phase I Fluconazole + Tazemetostat Omeprazole + Repaglinide + Tazemetostat Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, the Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and the Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma Subjects Active, not recruiting
NCT03037645 Phase Ib/II SNS-062 Safety, PK, PD, and Antitumor Activity of SNS-062 in B Lymphoid Cancers Recruiting
NCT03088878 Phase Ib/II Cirmtuzumab Cirmtuzumab + Ibrutinib Ibrutinib A Study of the Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies Recruiting
NCT03112174 Phase III Ibrutinib Ibrutinib + Venetoclax Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO) Recruiting
NCT03147885 Phase Ib/II Selinexor Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma Recruiting
NCT03153202 Phase Ib/II Ibrutinib + Pembrolizumab Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL) Recruiting
NCT03162536 Phase I ARQ 531 Safety, PK, PD, and Antitumor Activity of ARQ 531 in Hematologic Malignancies Recruiting
NCT03188965 Phase I BAY1895344 First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas Recruiting
NCT03189836 Phase I ACTR707 + Rituximab Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma Recruiting
NCT03219047 Phase I Ibrutinib The EXPLORE Trial: Study Evaluating Xenografts to Personalize Therapies (PDX) in Relapsed Mantle Cell Lymphoma to Optimize Response Recruiting
NCT03232307 Phase II Ibrutinib + Lenalidomide + Rituximab Ibrutinib Plus Rituximab and Lenalidomide in Elderly Patients With Newly Diagnosed Mantle Cell Lymphoma (MCL) Withdrawn
NCT03235544 Phase II Parsaclisib A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor (CITADEL-205) Recruiting
NCT03267433 Phase III Rituximab Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission Recruiting
NCT03282396 Phase II Ibrutinib Ibrutinib in Newly Diagnosed Mantle Cell Lymphoma With Low-Risk Disease Not yet recruiting
NCT03323151 Phase Ib/II Ibrutinib + Ixazomib A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma (PrE0404) Recruiting
NCT03379493 Phase I Study of ET190L1-ARTEMIS T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma Terminated
NCT03424122 Phase I Ibrutinib + Parsaclisib Bendamustine + Parsaclisib + Rituximab Parsaclisib + Rituximab INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112) Recruiting
NCT03424603 Phase I STRO-001 Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies Recruiting
NCT03440567 Phase I Avelumab + Carboplatin + Etoposide + Ifosfamide + Rituximab + Utomilumab Avelumab + Ibrutinib + Rituximab + Utomilumab Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma Recruiting
NCT03478514 Phase II Ibrutinib + Palbociclib Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma Recruiting
NCT03479268 Phase I Ibrutinib + MLN4924 Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma Recruiting
NCT03523975 Phase I Lenalidomide + Rituximab + Venetoclax Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma Recruiting
NCT03547115 Phase I Voruciclib A Phase 1 Study of Voruciclib in Subjects With B-Cell Malignancies Recruiting
NCT03557619 Phase I Ethinylestradiol + Levonorgestrel + Venetoclax A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Subjects With Different Hematological Malignancies Not yet recruiting
NCT03579927 Phase Ib/II Filgrastim iC9/CAR.19/IL15-Transduced CB-NK Carmustine + Cytarabine + Etoposide + Melphalan + Rituximab CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma Not yet recruiting
NCT03601819 Phase I Pacritinib Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders Recruiting
NCT03617484 Phase II Bortezomib + Ibrutinib Bortezomib in Combination With Ibrutinib in Ibrutinib Relapsed Mantle Cell Lymphoma Recruiting
NCT03623373 Phase I Acalabrutinib + Bendamustine + Cytarabine + Rituximab Acalabrutinib With Alternating Cycles of Bendamustine / Rituximab and Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma Recruiting
NCT03682796 Phase I TRPH-222 Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma Recruiting
NCT03684694 Phase I Ibrutinib + Loncastuximab tesirine Safety and Antitumor Activity Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma Recruiting
NCT03685344 Phase I Durvalumab + Loncastuximab tesirine Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma Recruiting
NCT03696784 Phase I Rimiducid Bendamustine + Fludarabine + iC9/CAR.19/IL15-Transduced CB-NK Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma Recruiting
NCT03710772 Phase II Ibrutinib + Rituximab + Venetoclax Cyclophosphamide + Dexamethasone + Doxorubicin + Rituximab + Vincristine Cytarabine + Methotrexate + Rituximab Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma Recruiting
NCT03779113 Phase Ib/II HMPL-523 An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma Recruiting
NCT03786926 Phase Ib/II HMPL-689 Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas Not yet recruiting
NCT03863184 Phase II Acalabrutinib + Lenalidomide + Rituximab Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL Not yet recruiting
NCT03872180 Phase II Bendamustine + Obinutuzumab + Venetoclax Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma Recruiting
NCT03877055 Phase Ib/II Copanlisib + Ibrutinib Ibrutinib A Study of Copanlisib and Ibrutinib in Mantle Cell Lymphoma Recruiting
NCT03920631 Phase I Nivolumab Microtransplantation and Checkpoint Blockade Immunotherapy for Relapsed or Refractory B Cell Lymphomas (MicroBLITZ) Not yet recruiting
NCT03939182 Phase Ib/II Abexinostat + Ibrutinib Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma Recruiting
NCT03946878 Phase II Acalabrutinib + Venetoclax Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma Not yet recruiting